-
Servier and Black Diamond Therapeutics Ink Global Deal for Solid Tumor Targeted Therapy BDTX-4933
•
French pharmaceutical firm Servier has announced a global licensing agreement with US-based Black Diamond Therapeutics (NASDAQ: BDTX) concerning BDTX-4933, a small molecule targeted therapy for solid tumors. The deal underscores a significant collaboration aimed at advancing the treatment landscape for multiple cancer indications. Deal Structure and Financial TermsUnder the agreement,…
-
Servier and Black Diamond Therapeutics Ink Global Deal for BDTX-4933
•
French pharmaceutical company Servier and US-based Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) announced a strategic global licensing agreement for BDTX-4933 on March 19, 2025. This collaboration aims to advance the development of BDTX-4933, a potential best-in-class targeted therapy for solid tumors. Drug ProfileBDTX-4933 is uniquely designed by Black Diamond to…
